EFFICACY AND SAFETY OF ADALIMUMAB AFTER INFLIXIMAB FAILURE IN PEDIATRIC ULCERATIVE COLITIS: A REAL-LIFE EXPERIENCE FROM THE SIGENP-IBD REGISTRY

(1) Sapienza University of Rome Dept. of Pediatric Gastroenterology SIGENP IBD Group,Pediatric Gastroenterology And Liver Unit,Rome,Italy

(2) Pediatric Department, Gastroenterology and Nutrition Unit,Institute for Maternal and Child Health, IRCCS “Burlo Garofalo,”,Trieste,Italy

(3) Institute “Giannina Gaslini”,Pediatric Gastroenterology Unit,Genova,Italy

(4) Pediatric Department,Pediatric Gastroenterology and Endoscopy, Pediatric Department,Messina,Italy

(5) Maggiore Hospital,Pediatric Gastroenterology Unit,Bologna,Italy

(6) Salesi Children Hospital,Pediatric Gastroenterology Unit,Ancona,Italy

(7) Spirito Santo Hospital,Pediatric Gastroenterology and Endoscopy Unit,Pescara,Italy

(8) Buzzi Children Hospital,Pediatric Department, Gastroenterology Unit,Milan,Italy

(9) "Bambino Gesù" Children Hospital,Gastroenterology and Nutrition Unit,Rome,Italy

(10) A.C.S. INTERNATIONAL PHARMA GROUP SRL,University Department of Pediatrics,Brescia,Italy

(11) GI Unit, Ospedale Maggiore , Bologna,Bologna,Italy



This item was part of UEG Week 2017

This item can be cited as: United European Gastroenterology Journal 2017; 5 (Supplement 1)